{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:54:42Z","timestamp":1787507682047,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-025-05945-w","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T20:05:06Z","timestamp":1764619506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mutant p53 regulates reversible subtype plasticity in pancreatic cancer"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6076-0090","authenticated-orcid":false,"given":"June-Ha","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9418-7061","authenticated-orcid":false,"given":"Hwa-Ryeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9994-3062","authenticated-orcid":false,"given":"Jae-Seok","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"5945_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cdd.2017.180","volume":"25","author":"EH Baugh","year":"2018","unstructured":"Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS (2018) Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 25(1):154\u2013160. https:\/\/doi.org\/10.1038\/cdd.2017.180","journal-title":"Cell Death Differ"},{"issue":"3","key":"5945_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1073\/pnas.96.3.1002","volume":"96","author":"J Brugarolas","year":"1999","unstructured":"Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA (1999) Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G 1 arrest after \u03b3-irradiation. Proc Natl Acad Sci U S A 96(3):1002\u20131007. https:\/\/doi.org\/10.1073\/pnas.96.3.1002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5945_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s1097-2765(01)00214-3","volume":"7","author":"K Nakano","year":"2001","unstructured":"Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7(3):683\u2013694. https:\/\/doi.org\/10.1016\/s1097-2765(01)00214-3","journal-title":"Mol Cell"},{"issue":"2","key":"5945_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","volume":"157","author":"S Weissmueller","year":"2014","unstructured":"Weissmueller S, Manchado E, Saborowski M, Morris JPT, Wagenblast E, Davis CA et al (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell. 157(2):382\u201394. https:\/\/doi.org\/10.1016\/j.cell.2014.01.066","journal-title":"Cell."},{"issue":"1","key":"5945_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13542-2","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen S, Wang Q, Yu H, Capitano ML, Vemula S, Nabinger SC et al (2019) Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nat Commun 10(1):5649. https:\/\/doi.org\/10.1038\/s41467-019-13542-2","journal-title":"Nat Commun"},{"issue":"7","key":"5945_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1158\/2159-8290.CD-18-1391","volume":"9","author":"E Loizou","year":"2019","unstructured":"Loizou E, Banito A, Livshits G, Ho YJ, Koche RP, Sanchez-Rivera FJ et al (2019) A gain-of-function p53-mutant oncogene promotes cell fate plasticity and myeloid leukemia through the pluripotency factor FOXH1. Cancer Discov 9(7):962\u2013979. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1391","journal-title":"Cancer Discov"},{"issue":"34","key":"5945_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2308807120","volume":"120","author":"D Dibra","year":"2023","unstructured":"Dibra D, Moyer SM, El-Naggar AK, Qi Y, Su X, Lozano G (2023) Triple-negative breast tumors are dependent on mutant p53 for growth and survival. Proc Natl Acad Sci U S A 120(34):e2308807120. https:\/\/doi.org\/10.1073\/pnas.2308807120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"5945_CR8","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1038\/onc.2012.334","volume":"32","author":"P Dong","year":"2013","unstructured":"Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H et al (2013) Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 32(27):3286\u20133295. https:\/\/doi.org\/10.1038\/onc.2012.334","journal-title":"Oncogene"},{"issue":"8","key":"5945_CR9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1101\/gad.181685.111","volume":"26","author":"PM Do","year":"2012","unstructured":"Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V et al (2012) Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 26(8):830\u2013845. https:\/\/doi.org\/10.1101\/gad.181685.111","journal-title":"Genes Dev"},{"issue":"2","key":"5945_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network, Cancer Genome Atlas Research N. (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32(2):185-203 e13. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.007","journal-title":"Cancer Cell"},{"issue":"1","key":"5945_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1073\/pnas.0908428107","volume":"107","author":"JP Morton","year":"2010","unstructured":"Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B et al (2010) Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107(1):246\u2013251. https:\/\/doi.org\/10.1073\/pnas.0908428107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5945_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1215995","volume":"14","author":"J Wang","year":"2023","unstructured":"Wang J, Liu W, Zhang L, Zhang J (2023) Targeting mutant p53 stabilization for cancer therapy. Front Pharmacol 14:1215995. https:\/\/doi.org\/10.3389\/fphar.2023.1215995","journal-title":"Front Pharmacol"},{"issue":"15","key":"5945_CR13","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1158\/0008-5472.CAN-20-3855","volume":"81","author":"J Wang","year":"2021","unstructured":"Wang J, Chen Y, Huang C, Hao Q, Zeng SX, Omari S et al (2021) Valosin-containing protein stabilizes mutant p53 to promote pancreatic cancer growth. Cancer Res 81(15):4041\u20134053. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3855","journal-title":"Cancer Res"},{"issue":"7592","key":"5945_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531(7592):47\u201352. https:\/\/doi.org\/10.1038\/nature16965","journal-title":"Nature"},{"issue":"6","key":"5945_CR15","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","volume":"155","author":"F Puleo","year":"2018","unstructured":"Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P et al (2018) Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology. 155(6):1999-2013 e3. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.033","journal-title":"Gastroenterology."},{"issue":"10","key":"5945_CR16","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA et al (2015) Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet 47(10):1168\u20131178. https:\/\/doi.org\/10.1038\/ng.3398","journal-title":"Nat Genet"},{"issue":"6","key":"5945_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107625","volume":"31","author":"H Brunton","year":"2020","unstructured":"Brunton H, Caligiuri G, Cunningham R, Upstill-Goddard R, Bailey UM, Garner IM et al (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Rep 31(6):107625. https:\/\/doi.org\/10.1016\/j.celrep.2020.107625","journal-title":"Cell Rep"},{"issue":"7","key":"5945_CR18","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.celrep.2018.10.051","volume":"25","author":"TDD Somerville","year":"2018","unstructured":"Somerville TDD, Xu Y, Miyabayashi K, Tiriac H, Cleary CR, Maia-Silva D et al (2018) TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma. Cell Rep. 25(7):1741\u201355 e7. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.051","journal-title":"Cell Rep."},{"issue":"1","key":"5945_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/j.gastro.2023.02.049","volume":"165","author":"HB Yoo","year":"2023","unstructured":"Yoo HB, Moon JW, Kim HR, Lee HS, Miyabayashi K, Park CH et al (2023) A TEAD2-driven endothelial-like program shapes basal-like differentiation and metastasis of pancreatic cancer. Gastroenterology. 165(1):133\u201348 e17. https:\/\/doi.org\/10.1053\/j.gastro.2023.02.049","journal-title":"Gastroenterology."},{"issue":"2","key":"5945_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101411","volume":"5","author":"V Ruta","year":"2024","unstructured":"Ruta V, Naro C, Pieraccioli M, Leccese A, Archibugi L, Cesari E et al (2024) An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Cell Rep Med 5(2):101411. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101411","journal-title":"Cell Rep Med"},{"issue":"1","key":"5945_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s43018-019-0010-1","volume":"1","author":"A Hayashi","year":"2020","unstructured":"Hayashi A, Fan J, Chen R, Ho YJ, Makohon-Moore AP, Lecomte N et al (2020) A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nat Cancer 1(1):59\u201374. https:\/\/doi.org\/10.1038\/s43018-019-0010-1","journal-title":"Nat Cancer"},{"issue":"1\u20132","key":"5945_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V et al (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell 160(1\u20132):324\u2013338. https:\/\/doi.org\/10.1016\/j.cell.2014.12.021","journal-title":"Cell"},{"issue":"5","key":"5945_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cell.2017.07.007","volume":"170","author":"JS Roe","year":"2017","unstructured":"Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B et al (2017) Enhancer reprogramming promotes pancreatic cancer metastasis. Cell. 170(5):875\u201388 e20. https:\/\/doi.org\/10.1016\/j.cell.2017.07.007","journal-title":"Cell."},{"issue":"1","key":"5945_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S et al (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635","journal-title":"Bioinformatics"},{"issue":"3","key":"5945_CR25","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nprot.2012.016","volume":"7","author":"C Trapnell","year":"2012","unstructured":"Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR et al (2012) Differential gene and transcript expression analysis of RNA-seq experiments with tophat and cufflinks. Nat Protoc 7(3):562\u2013578. https:\/\/doi.org\/10.1038\/nprot.2012.016","journal-title":"Nat Protoc"},{"issue":"25","key":"5945_CR26","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"184","author":"S Raghavan","year":"2021","unstructured":"Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE et al (2021) Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell. 184(25):6119\u201337 e26. https:\/\/doi.org\/10.1016\/j.cell.2021.11.017","journal-title":"Cell."},{"issue":"W1","key":"5945_CR27","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J (2015) Clustvis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res 43(W1):W566\u2013W570. https:\/\/doi.org\/10.1093\/nar\/gkv468","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"5945_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Genet 38(5):500\u2013501. https:\/\/doi.org\/10.1038\/ng0506-500","journal-title":"Nat Genet"},{"issue":"2","key":"5945_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1083\/jcb.201009059","volume":"192","author":"PA Muller","year":"2011","unstructured":"Muller PA, Vousden KH, Norman JC (2011) P53 and its mutants in tumor cell migration and invasion. J Cell Biol 192(2):209\u2013218. https:\/\/doi.org\/10.1083\/jcb.201009059","journal-title":"J Cell Biol"},{"issue":"23","key":"5945_CR30","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-11-0459","volume":"71","author":"YA Suh","year":"2011","unstructured":"Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK et al (2011) Multiple stress signals activate mutant p53 in vivo. Cancer Res 71(23):7168\u20137175. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-0459","journal-title":"Cancer Res"},{"issue":"1","key":"5945_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01117-y","volume":"8","author":"H Rahnamoun","year":"2017","unstructured":"Rahnamoun H, Lu H, Duttke SH, Benner C, Glass CK, Lauberth SM (2017) Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling. Nat Commun 8(1):754. https:\/\/doi.org\/10.1038\/s41467-017-01117-y","journal-title":"Nat Commun"},{"issue":"5947","key":"5945_CR32","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/science.1174229","volume":"325","author":"J Yun","year":"2009","unstructured":"Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H et al (2009) Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325(5947):1555\u20131559. https:\/\/doi.org\/10.1126\/science.1174229","journal-title":"Science"},{"issue":"3","key":"5945_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1083\/jcb.139.3.575","volume":"139","author":"MA Schwartz","year":"1997","unstructured":"Schwartz MA (1997) Integrins, oncogenes, and anchorage independence. J Cell Biol 139(3):575\u2013578. https:\/\/doi.org\/10.1083\/jcb.139.3.575","journal-title":"J Cell Biol"},{"issue":"31","key":"5945_CR34","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1038\/onc.2009.139","volume":"28","author":"S Mori","year":"2009","unstructured":"Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G et al (2009) Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28(31):2796\u20132805. https:\/\/doi.org\/10.1038\/onc.2009.139","journal-title":"Oncogene"},{"issue":"2","key":"5945_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O\u2019Kane GM et al (2020) Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet 52(2):231\u2013240. https:\/\/doi.org\/10.1038\/s41588-019-0566-9","journal-title":"Nat Genet"},{"issue":"18","key":"5945_CR36","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","volume":"26","author":"GM O\u2019Kane","year":"2020","unstructured":"O\u2019Kane GM, Grunwald BT, Jang GH, Masoomian M, Picardo S, Grant RC et al (2020) GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res 26(18):4901\u20134910. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3724","journal-title":"Clin Cancer Res"},{"key":"5945_CR37","doi-asserted-by":"publisher","unstructured":"Hur SK, Somerville TDD, Wu XS, Maia-Silva D, Demerdash OE, Tuveson DA, et al. (2023) p73 activates transcriptional signatures of basal lineage identity and ciliogenesis in pancreatic ductal adenocarcinoma. bioRxiv. https:\/\/doi.org\/10.1101\/2023.04.20.537667","DOI":"10.1101\/2023.04.20.537667"},{"issue":"1","key":"5945_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbamcr.2014.10.003","volume":"1853","author":"C Fiorini","year":"2015","unstructured":"Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M (2015) Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta 1853(1):89\u2013100. https:\/\/doi.org\/10.1016\/j.bbamcr.2014.10.003","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"5945_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/jp9.0000000000000146","volume":"6","author":"R Gong","year":"2023","unstructured":"Gong R, Hu Y, Yu Q, Fang L, Ren H (2023) Metabolic signatures in pancreatic ductal adenocarcinoma: diagnostic and therapeutic implications. J Pancreatol 6(4):185\u2013195. https:\/\/doi.org\/10.1097\/jp9.0000000000000146","journal-title":"J Pancreatol"},{"key":"5945_CR40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/HP.S52636","volume":"2","author":"A Yuen","year":"2014","unstructured":"Yuen A, Diaz B (2014) The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl) 2:91\u2013106. https:\/\/doi.org\/10.2147\/HP.S52636","journal-title":"Hypoxia (Auckl)"},{"issue":"3","key":"5945_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E et al (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656\u2013670. https:\/\/doi.org\/10.1016\/j.cell.2012.01.058","journal-title":"Cell"},{"key":"5945_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102057118","author":"W Palm","year":"2021","unstructured":"Palm W (2021) Metabolic plasticity allows cancer cells to thrive under nutrient starvation. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2102057118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5945_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01753-7","volume":"22","author":"HD Huh","year":"2023","unstructured":"Huh HD, Sub Y, Oh J, Kim YE, Lee JY, Kim HR et al (2023) Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination. Mol Cancer 22(1):63. https:\/\/doi.org\/10.1186\/s12943-023-01753-7","journal-title":"Mol Cancer"},{"issue":"18","key":"5945_CR44","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1101\/gad.304972.117","volume":"31","author":"R Pourebrahim","year":"2017","unstructured":"Pourebrahim R, Zhang Y, Liu B, Gao R, Xiong S, Lin PP et al (2017) Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein. Genes Dev 31(18):1847\u20131857. https:\/\/doi.org\/10.1101\/gad.304972.117","journal-title":"Genes Dev"},{"issue":"7568","key":"5945_CR45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nature15251","volume":"525","author":"J Zhu","year":"2015","unstructured":"Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M et al (2015) Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525(7568):206\u2013211. https:\/\/doi.org\/10.1038\/nature15251","journal-title":"Nature"},{"issue":"1","key":"5945_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cell.2009.01.039","volume":"137","author":"M Adorno","year":"2009","unstructured":"Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al (2009) A Mutant-p53\/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137(1):87\u201398. https:\/\/doi.org\/10.1016\/j.cell.2009.01.039","journal-title":"Cell"},{"issue":"5","key":"5945_CR47","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/cas.13214","volume":"108","author":"ND Sinh","year":"2017","unstructured":"Sinh ND, Endo K, Miyazawa K, Saitoh M (2017) Ets1 and ESE1 reciprocally regulate expression of ZEB1\/ZEB2, dependent on ERK1\/2 activity, in breast cancer cells. Cancer Sci 108(5):952\u2013960. https:\/\/doi.org\/10.1111\/cas.13214","journal-title":"Cancer Sci"},{"issue":"42","key":"5945_CR48","doi-asserted-by":"publisher","first-page":"39359","DOI":"10.1074\/jbc.M103429200","volume":"276","author":"J Sampath","year":"2001","unstructured":"Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH et al (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276(42):39359\u201339367. https:\/\/doi.org\/10.1074\/jbc.M103429200","journal-title":"J Biol Chem"},{"issue":"34","key":"5945_CR49","doi-asserted-by":"publisher","first-page":"13234","DOI":"10.1074\/jbc.RA118.003387","volume":"293","author":"H Rahnamoun","year":"2018","unstructured":"Rahnamoun H, Hong J, Sun Z, Lee J, Lu H, Lauberth SM (2018) Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4. J Biol Chem 293(34):13234\u201313246. https:\/\/doi.org\/10.1074\/jbc.RA118.003387","journal-title":"J Biol Chem"},{"issue":"1","key":"5945_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08362-x","volume":"21","author":"B Dhaka","year":"2021","unstructured":"Dhaka B, Sabarinathan R (2021) Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours. BMC Cancer 21(1):669. https:\/\/doi.org\/10.1186\/s12885-021-08362-x","journal-title":"BMC Cancer"},{"issue":"2","key":"5945_CR51","doi-asserted-by":"publisher","first-page":"188","DOI":"10.15252\/embr.201540488","volume":"17","author":"S Di Agostino","year":"2016","unstructured":"Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S et al (2016) YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep 17(2):188\u2013201. https:\/\/doi.org\/10.15252\/embr.201540488","journal-title":"EMBO Rep"},{"key":"5945_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.743908","volume":"9","author":"X Zhou","year":"2021","unstructured":"Zhou X, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R et al (2021) Clinical impact of molecular subtyping of pancreatic cancer. Front Cell Dev Biol 9:743908. https:\/\/doi.org\/10.3389\/fcell.2021.743908","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"5945_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/2159-8290.CD-22-0876","volume":"13","author":"C Falcomata","year":"2023","unstructured":"Falcomata C, Barthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D (2023) Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Discov 13(2):278\u2013297. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0876","journal-title":"Cancer Discov"},{"issue":"18","key":"5945_CR54","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1038\/s41388-018-0652-y","volume":"38","author":"I Ubby","year":"2019","unstructured":"Ubby I, Krueger C, Rosato R, Qian W, Chang J, Sabapathy K (2019) Cancer therapeutic targeting using mutant-p53-specific siRNAs. Oncogene 38(18):3415\u20133427. https:\/\/doi.org\/10.1038\/s41388-018-0652-y","journal-title":"Oncogene"},{"issue":"2","key":"5945_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1191","volume":"13","author":"L Kong","year":"2023","unstructured":"Kong L, Meng F, Wu S, Zhou P, Ge R, Liu M et al (2023) Selective degradation of the p53\u2013R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC. Clin Transl Med 13(2):e1191. https:\/\/doi.org\/10.1002\/ctm2.1191","journal-title":"Clin Transl Med"},{"issue":"4","key":"5945_CR56","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41565-023-01562-5","volume":"19","author":"X Huang","year":"2024","unstructured":"Huang X, Cao Z, Qian J, Ding T, Wu Y, Zhang H et al (2024) Nanoreceptors promote mutant p53 protein degradation by mimicking selective autophagy receptors. Nat Nanotechnol 19(4):545\u2013553. https:\/\/doi.org\/10.1038\/s41565-023-01562-5","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"5945_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01867-6","volume":"21","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang W, Hu B, Qin X, Yi T, Ye Y et al (2023) Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles. J Nanobiotechnology 21(1):117. https:\/\/doi.org\/10.1186\/s12951-023-01867-6","journal-title":"J Nanobiotechnology"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05945-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-025-05945-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-025-05945-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:20:04Z","timestamp":1768980004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-025-05945-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5945"],"URL":"https:\/\/doi.org\/10.1007\/s00018-025-05945-w","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to the updated funding note in the article","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have nothing to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no conflicts of the interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}